Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma

Haematologica

Volumn 99, Issue 12, 2014, Pages 1834-1845

  Jiang, Xin ^a   Guo, Honggang ^a   Wu, Jianguo ^a   He, Qiang ^b   Li, Yiqiao ^b   Wang, Miao ^c   Pan, Hongyang ^d   Li, Wande ^e   Wang, Jinjie ^a   Wang, Qingqing ^a   Shen, Jing ^a   Ke, Yuehai ^a   Zhou, Ren ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Epitomics Inc   (China)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; CD19 ANTIGEN; CYCLIN D2; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN TYROSINE PHOSPHATASE SHP 2; SHORT HAIRPIN RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; IMMUNOGLOBULIN HEAVY CHAIN; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PTPN11 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GERMINAL CENTER; GERMINAL CENTER LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE TRANSLOCATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GERMINAL CENTER; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOPRECIPITATION; LYMPHOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 84919396316     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.106401     Document Type: Article

References (50)

1. Tarlinton D. Germinal centers: form and function. Curr Opin Immunol. 1998;10(3): 245-51.
2. Wolniak KL, Shinall SM, Waldschmidt TJ. The germinal center response. Crit Rev Immunol. 2004;24(1):39-65.
3. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33.
4. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of Bcell differentiation. Nat Rev Immunol. 2002; 2(12):920-32.
5. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23.
6. Scheller H, Tobollik S, Kutzera A, Eder M, Unterlehberg J, Pfeil I, Jungnickel B. c-Myc overexpression promotes a germinal centerlike program in Burkitt’s lymphoma. Oncogene. 2010;29(6):888-97.
7. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777-83.
8. Huang JZ, Sanger WG, Greiner TC. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99(7):2285-90.
9. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol. 2005;560:125-39.
10. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med. 1993; 177(4):1209-13.
11. Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3- kinase. Science 1993; 260(5110):986-9.
12. van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901-12.
13. Sato S, Steeber DA, Jansen PJ, Tedder TF. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CDJ Immunol. 1997;158(10):4662-9.
14. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 1996;157(10):4371-8.
15. Rui L, Schmitz R, Ceribelli M, Staudt LM. Malignant pirates of the immune system. Nat Immunol. 2011;12(10):933-40.
16. Ghassemifar R, Forster L, Finlayson J, Calogero T, Augustson B, Joske D, et al. Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia. Pathology. 2012;44(7):632-7.
17. Roberts T, Snow EC. Cutting edge: recruitment of the CD19/CD21 coreceptor to B cell antigen receptor is required for antigenmediated expression of Bcl-2 by resting and cycling hen egg lysozyme transgenic B cells. J Immunol. 1999;162(8):4377-80.
18. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYCdriven B-lymphomagenesis. J Clin Invest. 2012;122(6):2257-66.
19. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol. 2012;189(5):2318-25.
20. Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Mycinduced lymphomagenesis. Cell Death Differ. 2012;19(7):1220-7.
21. Qu CK, Nguyen S, Chen J, Feng GS. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood. 2001;97(4):911-4.
22. Salmond RJ, Alexander DR. SHP2 forecast for the immune system: fog gradually clearing. Trends Immunol. 2006;27(3):154-60.
23. Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombo-poietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem. 2000;276(4): 2494-502.
24. Nishida K, Yoshida Y, Itoh M, Fukada T, Ohtani T, Shirogane T, et al. Gab-family adapter proteins act downstream of cytokine and growth factor receptors and Tand B-cell antigen receptors. Blood. 1999;93(6):1809-16.
25. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem. 2003; 278(43):41677-84.
26. Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol. 2000;20(5):1526-36.
27. Müller JP, Schönherr C, Markova B, Bauer R, Stocking C, Böhmer FD. Role of SHP2 for FLT3-dependent proliferation and transformation in 32D cells. Leukemia. 2008;22(10): 1945-8.
28. Ostman A, Hellberg C, Bohmer FD. Proteintyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6(4):307-20.
29. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900-11.
30. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012;18(4):529-37.
31. Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004;13(3):341-55.
32. Takahashi A, Tsutsumi R, Kikuchi I, Obuse C, Saito Y, Seidi A, et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011;43(1):45-56.
33. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325-31.
34. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465-8.
35. Grossmann KS, Rosario M, Birchmeier C, Birchmeier W. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010;106:53-89.
36. Xu R. Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. Cell Res. 2007;17(4): 295-7.
37. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M, Söderberg O, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007;48(11):2221-32.
38. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007;67(9):4278-86.
39. Brooks SR, Li X, Volanakis EJ, Carter RH. Systematic analysis of the role of CD19 cytoplasmic tyrosines in enhancement of activation in Daudi human B cells: clustering of phospholipase C and Vav and of Grb2 and Sos with different CD19 tyrosines. J Immunol. 2000;164(6):3123-31.
40. Otero DC, Omori SA, Rickert RC. Cd19- dependent activation of Akt kinase in B-lymphocytes. J Biol Chem. 2001;276(2):147-8.
41. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF- κB. EMBO J. 2002;21(15):4104-13.
42. De Leo A, Arena G, Lacanna E, Oliviero G, Colavita F, Mattia E. Resveratrol inhibits Epstein Barr virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets. Antiviral Res. 2012;96(2): 196-202.
43. Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D, Holzer R, et al. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol. 2007;8(1):57-63.
44. Nutt SL, Urbánek P, Rolink A, Busslinger M. Essential functions of PAX5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced Vto- DJ recombination at the IgH locus. Genes Dev. 1997;11(4):476-91.
45. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2005;14(19):2501-14.
46. Li X, Frye MA, Shelton RC. Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology. 2012; 37(1):77-101.
47. Kozmik Z, Wang S, Dörfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992; 12(6):2662.
48. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988; 71(1):13-29.
49. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1): 36.
50. Khattar E, Kumar V. Mitogenic regulation of p27(Kip1) gene is mediated by AP-1 transcription factors. J Biol Chem. 2010;285(7): 4554-61.